BSEOmkar Pharmachem LtdHighNeutral
Announced Thu, 29 May · 18:11 IST

Dear Sir, Please find enclosed the Intimation for appointment of Secretarial Auditor of the Company.

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

The board approved audited financial results for Q4 and FY ended March 31, 2025 along with the appointment of M/s. Maulik Bhavsar and Associates as Secretarial Auditor for five years (FY 2025-26 to FY 2029-30). The company reported no core sales from operations; total income was flat at around Rs. 54 lakh, similar to the previous year. Profit after tax rose about 6% to Rs. 20.09 lakh from Rs. 18.91 lakh, while EPS stood at Rs. 0.20 vs Rs. 0.19. The statutory auditor issued an unmodified (clean) opinion. Borrowings were sharply reduced from Rs. 30.31 lakh to Rs. 11.85 lakh, and the company generated positive operating cash flow of Rs. 24.35 lakh. Other equity remained negative at Rs. (65) lakh, though it improved from Rs. (85) lakh.

Likely market impact

Results are stable but the company has no real operating revenue and continues to carry negative reserves, so the stock remains a small, thinly-traded entity with limited business activity. The clean audit and reduced debt are mild positives, but there is no meaningful growth catalyst for shareholders.